Filing Flows › Chemed (CHE) › Q3 2026 › vs Q3 2025
Chemed (CHE) Q3 2026 vs Q3 2025 (year over year)
Chemed's revenue rose $66.0M (+11%) from $625M in Q3 2025 to $691M in Q3 2026. The biggest changes: VITAS +$49.7M (+12%); Roto-Rooter +$16.4M (+8%). Operating margin 14.0% against 12.0% (+2.0 pts).
Chemed, Q3 2026: revenue $691M (+11% year over year), operating margin 14.0%, net earnings $71.6M, operating cash flow $56.6M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 14.0% | 12.0% | +2.0 pts |
| Net margin | 10.4% | 10.3% | +0.1 pts |
| Free cash flow margin | 5.5% | 10.5% | -5.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| VITAS | $457M | $408M | $49.7M | +12% |
| Roto-Rooter | $234M | $217M | $16.4M | +8% |
| Revenue | $691M | $625M | $66.0M | +11% |
| Operating profit | $96.4M | $74.8M | $21.7M | +29% |
| Costs & expenses | $595M | $550M | $44.4M | +8% |
| Pre-tax earnings | $96.7M | $83.5M | $13.2M | +16% |
| Cost of revenue | $458M | $425M | $32.8M | +8% |
| SG&A | $111M | $106M | $5.7M | +5% |
| Other operating costs | $25.1M | $19.2M | $5.8M | +30% |
| Net earnings | $71.6M | $64.2M | $7.4M | +12% |
| Income tax | $25.1M | $19.3M | $5.8M | +30% |
| Depreciation & amortization | $17.4M | $16.2M | $1.2M | +7% |
| Working capital & other | $32.5M | −$2.9M | $35.4M | — |
| Operating cash flow | $56.6M | $83.4M | −$26.8M | -32% |
| Free cash flow (OCF − capex) | $37.9M | $65.9M | −$28.0M | -43% |
| Capital expenditures | $18.7M | $17.5M | $1.2M | +7% |
Questions
How much did Chemed's revenue grow year over year in Q3 2026?
Chemed's revenue rose $66.0M (+11%) from $625M in Q3 2025 to $691M in Q3 2026.
What drove Chemed's revenue change in Q3 2026?
VITAS +$49.7M (+12%); Roto-Rooter +$16.4M (+8%).